In patients with overt leukemia an alternative to immunization would be therapies that spare T cells but lead to rapid leukemia apoptosis to promote cross-presentation, such as gemtuzumab, an anti-CD33 immunotoxin63. The gene discussed is CD33; the disease is leukemia.